19:36 , Apr 20, 2018 |  BC Week In Review  |  Financial News

Bellicum raises $60M in follow-on

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) raised $60 million through the sale of 8 million shares at $7.50 in a follow-on underwritten by Citigroup, Jefferies, Guggenheim, Ladenburg Thalmann and Raymond James. The price is a 16% discount...
16:47 , Apr 18, 2018 |  BC Extra  |  Financial News

Bellicum prices $60M follow-on

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) raised $60 million through the sale of 8 million shares at $7.50 in a follow-on underwritten by Citigroup, Jefferies, Guggenheim, Ladenburg Thalmann and Raymond James. The price is a 16% discount...
18:18 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on trials of BPX-501

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA lifted a clinical hold on U.S. trials of the company’s adjunct, safety switch-containing T cell therapy BPX-501. FDA placed the hold in January after the company reported three cases...
23:19 , Apr 11, 2018 |  BC Extra  |  Clinical News

FDA lifts hold on Bellicum’s adjunct T cell therapy

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) gained $1.74 (25%) to $8.59 in after-hours trading Wednesday after FDA lifted a clinical hold on U.S. trials of the company’s adjunct, safety switch-containing T cell therapy BPX-501. FDA placed the...
16:44 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Bellicum reports OS rates from Phase I/II of adjunct T cell therapy BPX-501

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported data from 38 pediatric patients with acute myelogenous leukemia (AML) and 59 patients with primary immunodeficiencies undergoing a haploidentical hematopoietic stem cell transplant (HSCT) in the Phase I/II BP-004 trial...
22:55 , Mar 1, 2018 |  BC Week In Review  |  Clinical News

Bellicum planning changes to end clinical hold

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA has outlined criteria required to lift the agency's clinical hold on U.S. trials of adjunct T cell therapy BPX-501. The treatment, which consists of genetically modified donor cells and...
19:01 , Feb 23, 2018 |  BC Extra  |  Clinical News

Bellicum planning changes to end clinical hold

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA has outlined criteria required to lift the agency's clinical hold on U.S. trials of adjunct T cell therapy BPX-501. The treatment, which consists of genetically modified donor cells and...
20:15 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Bellicum announces trial holds for switch T cell candidates

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA placed a clinical hold on U.S. trials of the company's adjunct, safety switch-containing T cell therapy BPX-501 in patients receiving partial match hematopoietic stem cell transplants (HSCTs). According to...
00:55 , Feb 1, 2018 |  BC Extra  |  Clinical News

Bellicum falls on T cell therapy U.S. trial holds

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) fell $2.12 (26%) to $6.08 on Wednesday after it said FDA placed a clinical hold on U.S. trials of the company's adjunct, safety switch-containing T cell therapy BPX-501 in patients receiving...
17:58 , Mar 24, 2017 |  BC Extra  |  Financial News

Bellicum raises $60M in follow-on

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) raised $60 million through the sale of 5 million shares at $12 in a follow-on underwritten by Citigroup, Jefferies, Guggenheim, Ladenburg Thalmann, Raymond James and SunTrust. The price was a 16%...